Therapeutic Enoxaparin Dosing
The standard therapeutic dose of enoxaparin is 1 mg/kg subcutaneously every 12 hours for patients with normal renal function (CrCl ≥30 mL/min), with mandatory dose reduction to 1 mg/kg once daily for severe renal impairment (CrCl <30 mL/min). 1, 2
Standard Dosing Algorithm
For Acute Coronary Syndromes (ACS)
Initial therapy:
- 1 mg/kg subcutaneously every 12 hours for patients with normal renal function 1, 2
- Continue for duration of hospitalization or up to 8 days 3
Age-specific modifications for STEMI with fibrinolysis:
- Age <75 years: 30 mg IV bolus, then 1 mg/kg SC every 12 hours (maximum 100 mg for first 2 doses) 1, 2
- Age ≥75 years: No IV bolus, 0.75 mg/kg SC every 12 hours (maximum 75 mg for first 2 doses) 1, 2, 4
For Venous Thromboembolism (VTE)
Standard treatment dose:
- 1 mg/kg subcutaneously every 12 hours OR
- 1.5 mg/kg subcutaneously once daily 5
Both regimens are FDA-approved and equally effective for VTE treatment 3.
Renal Impairment Adjustments
This is the most critical adjustment and must not be missed:
- CrCl ≥30 mL/min: Standard dosing (1 mg/kg every 12 hours)
- CrCl <30 mL/min: Reduce to 1 mg/kg once daily (every 24 hours) 1, 2, 6, 4, 6
The 2025 ACC/AHA guidelines explicitly state this dose reduction is mandatory regardless of indication 1, 2. Enoxaparin clearance decreases by 31% with moderate renal impairment (CrCl 30-60 mL/min) and 44% with severe impairment (CrCl <30 mL/min), leading to 2-3 fold increased bleeding risk without adjustment 6, 7.
Important caveat: Some evidence suggests dose reduction may be warranted even for CrCl 30-50 mL/min, particularly with prolonged therapy (>10 days) 7, 8. Consider using 0.8 mg/kg every 12 hours for moderate impairment (CrCl 30-50 mL/min) based on pharmacokinetic data 7.
Calculate CrCl using Cockcroft-Gault equation (not eGFR), as this was used in clinical trials 8.
Obesity Adjustments
Contrary to common practice, do NOT routinely reduce doses or cap doses in obesity.
- Use actual body weight for dosing up to very high weights 9, 10, 11, 12
- Standard 1 mg/kg dosing in obesity often results in supratherapeutic levels and increased bleeding 10, 12
For severe obesity (BMI ≥40 kg/m² or weight >140 kg):
- Consider dose reduction to 0.75-0.85 mg/kg every 12 hours 10, 12
- This reduced range achieves therapeutic anti-Xa levels in 62-66% of patients versus only 42% with standard dosing 10, 12
- 85% of bleeding events in obese patients occurred with doses ≥0.95 mg/kg 10
Alternative approach for extreme obesity:
- Use IBW + 40% of excess weight or LBW + 40% as dosing weight 11
- This provides better correlation with therapeutic anti-Xa levels than actual body weight in BMI ≥30 kg/m² 11
Do not "dose cap" at arbitrary weights (e.g., 100 kg maximum dose) as this leads to subtherapeutic dosing and thrombotic risk 12.
Special Populations
Low Body Weight (<50 kg)
- Limited data, but consider dose reduction to 30 mg every 12 hours for prophylactic dosing 13
- For therapeutic dosing, use standard weight-based calculation but monitor closely
- Bleeding risk may be increased with standard dosing 13
Monitoring Considerations
Anti-Xa monitoring is NOT routinely required but should be considered in:
- Severe renal impairment (CrCl <30 mL/min) on prolonged therapy 6, 14
- Extreme obesity (weight >190 kg or BMI ≥40 kg/m²) 10, 12, 8
- Pregnancy (not covered in provided evidence)
- Therapeutic failure or bleeding complications
Target therapeutic anti-Xa range: 0.5-1.0 IU/mL (or 0.5-1.2 IU/mL per some sources) 7
Additional Risk Factors for Supratherapeutic Levels
Beyond renal impairment and obesity, female sex, lower BMI, concomitant corticosteroids, and multiple doses increase risk of supratherapeutic anti-Xa levels 15. Consider empiric dose reduction or earlier monitoring in patients with multiple risk factors.
Critical Safety Points
Never switch between enoxaparin and unfractionated heparin during treatment - this significantly increases bleeding risk 4.
For PCI procedures in patients already on enoxaparin:
- If last dose <8 hours ago: No additional dosing needed
- If last dose 8-12 hours ago: Give 0.3 mg/kg IV bolus
- If no prior enoxaparin: Give 0.5-0.75 mg/kg IV bolus 1, 2
The most common dosing error is failure to adjust for severe renal impairment, which substantially increases bleeding risk without improving efficacy 6, 7.